Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cervarix, Gardasil Set For FDA Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.

You may also be interested in...

Merck Vaccine President Slot Opens Up With McGlynn's Retirement

A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.

Glaxo Boasts Its Cervarix Vaccine Protects Against Five Most Common HPV Strains

The drug maker hopes the data will reverse a long-delayed approval in the U.S., where Merck's Gardasil has a commanding lead.

Sticking Point: Cervarix Outshines Gardasil, But Practical Value Is Unclear

Merck says immune response trial provides "no clinically relevant information."

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts